Temporal Outcomes of Patients Diagnosed With Transthyretin Cardiac Amyloidosis
Journal of Cardiac Failure · 2024
DOI: 10.1016/j.cardfail.2024.02.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2024. Verfasst von Nicholas Chan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York Presbyterian…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly recognized. Clinical outcomes have evolved over time amid changes in the diagnostic pathway and advances in therapeutics. We sought to evaluate clinical outcomes over time of patients with ATTR-CA with access to disease-modifying therapy. METHODS AND RESULTS: This is a retrospective cohort study of 419 patients diagnosed with ATTR-CA during 2001-2021, comparing clinical characteristics across eras. The primary end point was composite all-cause mortality or orthotopic heart transplantation (OHT). Time-to-event analysis was performed using Cox proportional hazard modeling controlling for differences among cohorts. Patients diagnosed in the more recent years had higher median age (2017-2021, 78 years; 2014-2016, 75 years; 2001-2013, 74 years) and more often had wild-type ATTR (81.9% vs 82.5% vs 56.4%), but less severe phenotypes as evidenced by more individuals with Columbia stage I disease (47.6% vs 35.9% vs 22.4%), owing to lower biomarkers, more patients in New York Heart Association functional classes I and II (68.9% vs 47.6% vs 43.6%), and lower use of loop diuretics (67.0% vs 78.6% vs 89.1%). Over time, patients were treated more frequently with tafamidis (74% vs 37% vs 32%). On multivariable analysis, greater Columbia score (hazard ratio 1.42, 95% confidence interval 1.30-1.54, P < .001) was predictive of death or OHT, whereas tafamidis (hazard ratio 0.31, 95% confidence interval 0.22-0.44, P < .001) was associated with greater survival and freedom from OHT. CONCLUSIONS: Patients recently diagnosed with ATTR-CA have earlier stage disease and substantially lower mortality. Tafamidis is associated with significantly improved survival and freedom from OHT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York, New York; Clinical Cardiovascular Research Labora…
Förderung
- NIA NIH HHS
- NHLBI NIH HHS
- NCATS NIH HHS
- NIH
Zitieren
APA
Chan, N., Teruya, S., Mirabal, A., Weinsaft, A. Y., Santos, J. L., Guadalupe, S., Jimenez, M., Rodriguez, C., Helmke, S., Cuomo, M., Smiley, D., & Maurer, M. S. (2024). Temporal Outcomes of Patients Diagnosed With Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2024.02.014
Vancouver
Chan N, Teruya S, Mirabal A, Weinsaft AY, Santos JL, Guadalupe S, et al. Temporal Outcomes of Patients Diagnosed With Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure. 2024. doi:10.1016/j.cardfail.2024.02.014
BibTeX
@article{Chan2024,
author = {Chan, Nicholas and Teruya, Sergio and Mirabal, Alfonsina and Weinsaft, Ariel Y and Santos, Jeffeny DE Los and Guadalupe, Samantha and Jimenez, Massiel and Rodriguez, Carlos and Helmke, Stephen and Cuomo, Margaret and Smiley, Dia and Maurer, Mathew S},
title = {Temporal Outcomes of Patients Diagnosed With Transthyretin Cardiac Amyloidosis},
journal = {Journal of Cardiac Failure},
year = {2024},
doi = {10.1016/j.cardfail.2024.02.014}
}
EUVIMED